tbuckley/cabot-search huggingface dataset:
Abstract 2387: Co-Localisation of C-Reactive Protein and the Terminal Complement Complex in Dilated Cardiomyopathy - Implications for Non-Ischaemic Heart Failure
Authors: Oliver Zimmermann, Dimitar E Manolov, Ziya Kaya, Thomas P Zwaka, Magdalena Bienek-Ziolkowski, Bettina Wolf, Vinzenz Hombach, Jan Torzewski
Journal: Circulation (2007)

Background: C-reactive protein (CRP) has been suggested as a risk factor in cardiovascular disease. Recently, it has been shown that CRP binds to ligands exposed in ischaemic damaged tissue and activates the complement system. Furthermore, CRP was demonstrated to be strongly and independently associated with the occurrence of heart failure in men. In this study we have investigated the presence of CRP and the Terminal Complement Complex (C5b-9) in the myocardium of patients suffering from non-ischaemic heart failure. Methods and Results: Endomyocardial biopsies were taken from 151 patients suffering from dilated cardiomyopathy. Biopsies were immunohistochemically analysed for the presence and distribution pattern of CRP and C5b-9. In 39 patients plasma levels of hsCRP and NT-proBNP were measured and correlated with myocardial biopsy findings. In 47 patients a positive staining for CRP and in 141 patients a positive staining for C5b-9 was detected. CRP and C5b-9 significantly co-localised within the myocardium. A negative correlation was observed for plasma hsCRP levels and myocardial CRP. Conclusions: This study shows for the first time that CRP is frequently present in the myocardium of patients suffering from non-ischaemic dilated cardiomyopathy and co-localises with the Terminal Complement Complex. CRP may contribute to myocardial damage in dilated cardiomyopathy via activating the complement system.
Bathers on the Rocks
Authors: M. Therese Southgate
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 3716: Endothelial-specific Deletion Of The Gap Junction Protein Connexin43 Reduces Atherosclerosis In Mice
Authors: Sandrine Morel, Esther Sutter, Isabelle Roth, Bernard Foglia, Urban Deutsch, Martin Theis, Brenda R Kwak
Journal: Circulation (2008)

Decreasing the expression of the gap junction protein connexin43 (Cx43) in mice provides beneficial effects on both the progression and composition of the atherosclerotic lesions. During atherosclerotic lesion development, Cx43 expression is temporarily up-regulated in intimal smooth muscle cells, induced in macrophages close to the lipid core and triggered in a subset of endothelial cells covering the shoulder of atherosclerotic lesions. The purpose of this study was to examine the role of endothelial Cx43 in the development of atherosclerosis in vivo. For this purpose, we have used the Cre-loxP system to create an atherosclerosis-susceptible mouse line in which Cx43 is deleted from the endothelium only. The natural progression of atherosclerosis and the composition of the atherosclerotic lesions were studied in 18 month-old male TIE2Cre+ Cx43fl/fl ApoE−/− mice and TIE2Cre- Cx43fl/fl ApoE−/− littermate controls. Body weights were not different between both groups. Interestingly, the progression of atherosclerosis (measured as % of surface stained with Sudan IV) was significantly reduced in the thoracic-abdominal aorta of TIE2Cre+ Cx43fl/fl ApoE−/− mice (21.53±7.14%; N=4) compared with TIE2Cre- Cx43/fl/fl ApoE−/− controls (46.84±11.60%, N=6, P&lt;0.05). In addition, advanced atheroma in TIE2Cre+ Cx43fl/fl ApoE−/− mice contained less lipids and showed decreased calcium deposition compared with lesions in TIE2Cre- Cx43fl/fl ApoE−/− controls. Thus, endothelial-specific deletion of Cx43 in mice provides beneficial effects on both the natural progression and composition of the atherosclerotic lesions. Future studies are aimed at obtaining insight into the participation of Cx43 in macrophages and smooth muscle cells in atherosclerosis.
Abstract 12072: The Association of Thromboembolic Complications and Blood Group in Patients with Atrial Fibrillation
Authors: Jodi M Blustin, Robert D McBane, Diane E Grill, Naser Ammash, Matylda Mazur, Ondrej Sochor, Waldemar Wysokinski
Journal: Circulation (2011)

BACKGROUND. Elevated Von Willebrand Factor (VWF) levels are associated with an increased risk of stroke in atrial fibrillation (AF). Individuals with blood group O are known to have 20-30% lower VW...
Abstract 5065: Outpatient Treatment of Severe Intermittent Claudication with Intravenous Pge1: The Oracle Study. Efficacy and Costs. Improvement in Cardiovascular Morbidity/Mortality
Authors: Gianni Belcaro, Umberto Cornelli, Maria Rosaria Ceesarone, Andrea Di Renzo, Edmondo Ippolito
Journal: Circulation (2008)

Efficacy and costs of prostaglandin E1 (PGE1) treatment in severe intermittent claudication (walking distance <50 m), in subjects with concomitant severe coronary disease, was studied using in a 30...
Physician Burnout
Authors: S. S. Chopra
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cerebral Vasodilators
Authors: Jan Koch-Weser, Peter Cook, Ian James
Journal: New England Journal of Medicine (1981)

Drugs Acting on AdrenoreceptorsIsoxsuprine Pharmacology Isoxsuprine is a phenylethylamine derivative of epinephrine. The compound is said to be an alpha-adrenoreceptor antagonist with beta-adrenoreceptor-stimulating properties, but the vasodilator effects on muscle blood flow are not prevented by beta-adrenoreceptor blockade.78 The drug also lowers blood viscosity and inhibits platelet aggregation when given in high doses.79 Effect on Cerebral Blood Flow Intravenous isoxsuprine produces both cerebral and peripheral vasodilatation. A fall in blood pressure occurs and is not fully compensated by the decrease in cerebrovascular resistance; a small reduction in cerebral blood flow results.29,51, 80 Effect on Cerebrovascular Disease and Dementia Three double-blind, . . .
Abstract 19655: AVR Elevation Predicts Early Revascularization but not Cardiac Events in Patients Undergoing Exercise Stress Myocardial Perfusion Imaging
Authors: Aparna Baheti, Michael McArdle, George Beller, Jamieson Bourque
Journal: Circulation (2012)

Introduction: Lead AVR elevation has been associated with a high prevalence of multivessel disease in patients undergoing exercise stress. Myocardial perfusion imaging (MPI) may be falsely negative in multivessel disease due to balanced ischemia, leading to false reassurance. We sought to identify the prevalence of early revascularization and subsequent cardiac events in a cohort undergoing exercise stress SPECT MPI. Methods: We analyzed clinical data and prospectively-collected events on a cohort of 587 consecutive patients referred for exercise SPECT MPI. Standard exercise protocols were used. AVR elevation was defined as ≥1mm in 3 consecutive beats. Follow-up was 98% complete with a median time of 3.75 years. Cardiac events included cardiac death and nonfatal myocardial infarction. Early revascularization rates were compared by chi-square analysis. The effect of AVR elevation on cardiac events was assessed using Cox proportional hazards analysis. Results: The cohort had a median age of 60.0 years and 61.4% were male. Patients with AVR elevation had a higher prevalence of hypertension, dyslipidemia, and known CAD. Early revascularization was 10-fold higher in patients with AVR-elevation (8.3% versus 0.81%, p&lt;0.001). In the 568 patients without early revascularization, there were 24 cardiac events (1.1%/year), of whom only 10 (41.7%) had AVR elevation on their initial stress test. AVR elevation was not a significant predictor of cardiac events by Cox analysis (Hazard Ratio 2.0 (95% CI 0.8-5.1), p=0.137). Conclusion: AVR elevation on exercise electrocardiography strongly predicts early revascularization. However, there was a low cardiac event rate in the remaining patients, and events were not predicted by AVR elevation. This idicates a low risk of clinically significant false-negative SPECT in this subgroup.
Outbreak of Salmonella enterica serotype Manhattan infection associated with meat products, France, 2005
Authors: H Noël, M Dominguez, F X Weill, A Brisabois, C Duchazeaubeneix, A Kerouanton, G Delmas, N Pihier, E Couturier
Journal: Eurosurveillance (2006)

Between August 2005 and March 2006 in France, 69 cases of Salmonella enterica serotype Manhattan (Salmonella Manhattan) were reported, 51 (74%) of them from southeastern France. At the time of the alert (November 2005), 13 cases and 33 controls were interviewed. Cases were more likely than controls to have eaten pork sausages (OR=5.9, confidence interval CI [1.3; 26.9]) and beef (OR=9.3, CI [1.3; 68.6]). At the same time, 19 strains of Salmonella Manhattan isolated from meat products in southeastern France, reported to the French food safety agency (Afssa, Agence francaise de securite sanitaire des aliments) in September and November 2005, had an indistinguishable PFGE profile to the 7 human isolates of Salmonella Manhattan from the outbreak in southeastern France. Trace-back investigations revealed that pork samples came from one wholesaler whose pork products had tested positive for S. Manhattan during routine food testing in August 2005. This wholesaler supplied retail outlets in southeastern France. Additionally, a slaughterhouse supplying the wholesaler was inspected and widespread contamination with Salmonella spp. and S. Manhattan was found. Cooperation between the national agencies in charge of human health (Institut de veille sanitaire, InVS) and food safety (Afssa) allowed us to determine the most probable source of contamination and to take appropriate control measures.
Abstract 18228: Cost-Effectiveness of New Oral Antiplatelet Agents and Testing Strategies During Early Invasive Management of Acute Coronary Syndrome Patients
Authors: William B Hillegass, Gilbert Zoghbi, Brigitta C Brott, Meredith L Kilgore, Gregory D Chapman, Vijay K Misra
Journal: Circulation (2011)

BACKGROUND: Prasugrel has become available with variable adoption across practices. Incremental cost-effectiveness analysis of prasugrel and other future agents relative to clopidogrel may provide rationale guidance for their appropriate use. METHODS: A Markov-model with baseline acute coronary syndrome (ACS) health state and subsequent death, nonfatal myocardial infarction, stent thrombosis, urgent revascularization, major bleeding, and malignancy was constructed with 15 one month cycles. Published incremental costs, utilities, and event frequency distributions from randomized trials and series were used to assign transition probabilities and “payoffs” as a function of time. A second model examined modification of therapy at critical time-points based on genetic and platelet function testing assays. Probabilistic 95% confidence intervals were calculated using the parameter distributions in the model. RESULTS: In ACS patients undergoing an early invasive strategy, prasugrel was dominant over clopidogrel with $9,988+/-2,148 saved per QALY saved in the first month after the index event. In months 2 through 15, prasugrel 10 mg daily had incremental estimated cost of $5,820 +/- 2,136 per QALY saved. In months 2 through 15, prasugrel had estimated incremental cost-effectiveness of $42,225 +/-12,499 per QALY saved compared to generic clopidogrel (at lowest current online overseas price.) A strategy of early routine prasugrel administration in all eligible patients followed by genetic testing for loss-of-function CYP450-2C19 gene alleles to guide maintenance therapy was the most cost-effective strategy reducing overall societal cost by 36 +/- 18% with little compromise in net clinical outcomes. CONCLUSIONS: The estimated cost-effectiveness of oral antiplatelet adjunctive therapy in ACS patients being managed with an early invasive strategy is time-dependent and optimized by genetic testing. This analysis might help guide rationale selection of oral antiplatelet therapy, reducing arbitrary practice variation.
Buprenorphine versus heroin dependence: comparison of toxicologic and psychopathologic characteristics
Authors: M Torrens, L San, J Camí
Journal: American Journal of Psychiatry (1993)

Sociodemographic, toxicologic, and psychopathologic characteristics of 22 buprenorphine addicts and 45 heroin addicts admitted for inpatient detoxification were compared. Although the buprenorphine addicts were older, clinically significant differences were not apparent. The availability of buprenorphine may be the main reason for its abuse.
Abstract 5604: Door-to-Balloon Time - Are We Evaluating the Wrong Metric?
Authors: J. Mark Peterman, Anil George, Gregory R Giugliano, Marc J Schweiger
Journal: Circulation (2008)

Primary Percutaneous Coronary Intervention (PPCI) for STEMI is a time-sensitive process, commonly assessed by door-to-balloon time (D2B). Indeed, agencies responsible for tracking the success of an institution’s program and those setting reimbursement have established D2B among its core measures of quality. However, reperfusion of the infarct-related artery (IRA) can occur at times other than that of the initial balloon or device deployment. Therefore, we hypothesized that door-to-reperfusion time (D2R) differs significantly from D2B. We studied 68 consecutive patients who presented to our ER with STEMI and underwent PPCI between December 17, 2007 and June 1, 2008. D2B (time from ER arrival to the first use of an intracoronary balloon or thrombectomy device in the IRA) and D2R (time from ER arrival to the first documentation of TIMI 2 or 3 flow in the IRA) were recorded for each patient. All patients received aspirin, unfractionated heparin, and eptifibatide pre-procedure. In our series of 68 consecutive cases, D2R was equal to (11pts) or shorter than (44 pts) D2B in 55 (81%) patients. D2R occurred in a median of 59 min (IQR 49 – 70.5 min) and D2B in a median of 65 min (IQR 53–75.5 min). The difference between D2B and D2R was highly statistically significant (median +3 min, IQR 0 to 8 min, Wilcoxon p &lt; 0.0001). Additional device and/or drug therapy beyond the initial balloon inflation was required to establish TIMI 2–3 flow in 9% (6/68) of cases. D2B was longer than 90 minutes when D2R was less than 90 minutes in 3 of 68 (4%) cases. Our findings indicate that in PPCI, D2B commonly overestimates, and occasionally underestimates, D2R. D2R &lt; D2B was attributable to pre-procedural anticoagulants or guidewire crossing of the occlusion. Considering that coronary reperfusion, which correlates with myocardial salvage, is the goal of PPCI, D2R appears to be the better metric by which to judge quality of care. Use of this more accurate metric may allay an unnecessary and inappropriate force to rush to device therapy.
Abstract 3660: Signal-Responsive Repression of Notch1 Signaling by the Sirt1 Deacetylase Regulates Sprouting Angiogenesis
Authors: Michael Potente, Virginia Guarani, Danila Baldessari, Sohail Ejaz, Raul Mostoslavsky, Ingrid Fleming, Marina Mione, Frederick W Alt, Andreas M Zeiher, Stefanie Dimmeler
Journal: Circulation (2008)

The SIRT1 deacetylase is the closest mammalian homologue of yeast Sir2, which regulates life span in response to caloric restriction. A previous study from our laboratory identified SIRT1 as a key ...
Sweet's syndrome.
Authors: E Vance, S Granter, A Skarin
Journal: Journal of Clinical Oncology (1997)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1997.15.2.860 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 9053514 Sweet's syndrome. E VancexE VanceSearch for articles by this author , S GranterxS GranterSearch for articles by this author , A SkarinxA SkarinSearch for articles by this author Show More Dana-Farber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA. https://doi.org/10.1200/JCO.1997.15.2.860 PDF "Sweet's syndrome.." Journal of Clinical Oncology, 15(2), pp. 860–861© 1997 by American Society of Clinical Oncology
The Biology of Tissue Transplantation
Authors: Paul S. Russell, Anthony P. Monaco
Journal: New England Journal of Medicine (1964)

Subcellular Fractions Involved in Allograft SensitivityRecent years have seen extensive investigation in which it has been found that subcellular fractions may be involved in the transfer of allograft sensitivity. Attention has been paid to the possibility that viable sensitized cells capable of transferring allograft sensitivity may do so by passing on material, thought by some to be a special type of antibody100, 104 to the reticuloendothelial cells of the host, enabling them to act as if they themselves had been directly sensitized.Lawrence and his co-workers have studied the problem extensively in man, in whom the situation has appeared to . . .
Suppressor-Cell Dysfunction in Systemic Lupus Erythematosus
Authors: Akira Sagawa, Nabih I. Abdou
Journal: Journal of Clinical Investigation (1978)

To characterize the cell(s) responsible for the suppressor-cell dysfunction in active systemic lupus erythematosus (SLE), we fractionated blood mononuclear cells into thymus-derived (T), bone marrow-derived (B), and monocyte-depleted populations. Various cell populations from active SLE, inactive SLE, or normals, were activated with Concanavalin A, washed, and then co-cultured with active SLE cells. Soluble immune response suppressor (SIRS) from culture supernates of the activated cells was also used for the possible correction of the suppressor-cell dysfunction. Suppression was tested by enumerating DNA-binding cells by radioautography and by quantitating anti-DNA antibody in culture supernates by radioimmunoassay; and immunoglobulin was tested in cells and supernates by the immunofluorescence and the immunofluor techniques, respectively. Except for the numbers of DNA-binding cells, which were not suppressed, all the other three parameters in co-cultures with cells from active SLE patients were suppressed by Concanavalin A-activated cells (P < 0.001), or by SIRS (P < 0.05) from normals or inactive SLE patients. Concanavalin A-activated autologous or allogeneic active SLE cells and nonactivated cells from active or inactive SLE failed to suppress the various B-cell functions. Nonactivated normal cells suppressed levels of anti-DNA and immunoglobulin in supernates (P < 0.05).
Abstract 3181: Myocardial Injury Induces the Expansion and Cardiomyogenic Differentiation of Postnatal Nkx2.5 Progenitor Cells via Inflammatory Signals
Authors: Yuan-Hung Liu, David Rawnsley, Ming Zeng, Esther Yu, Daniel Pijnappels, Helene Thibault, Marielle Scherrer-Crosbie, Sean M Wu
Journal: Circulation (2009)

Recent studies have demonstrated the capacity of postnatal mammalian heart to undergo cardiomyocyte renewal; however, evidence is lacking for a direct progenitor cell role in this process. Using an...
Public health psychiatry and crime prevention
Authors: J. J Sandford, D. Summerfield
Journal: BMJ (1999)

Intranasal corticosteroids in allergic rhinitis Paper did not include all data on adverse effectsEditor-Weiner et al conclude that "results from [their] systematic review, together with data on safety and cost effectiveness, support the use of intranasal corticosteroids over oral antihistamines as first line treatment for allergic rhinitis." 1 They also state that "intranasal corticosteroids are considered safe [and] studies have failed to show significant effects on serum markers of bone metabolism and short term bone growth," referring to two studies, those by Martinati et al and Wolthers et al.They make no reference to two more recent studies, both of a larger number of subjects over longer periods, which established a significant reduction in paediatric bone growth. 2 3The issue of adverse effects was also addressed in a report by the Committee on Safety of Medicines and Medicines Control Agency, which concluded that intranasal corticosteroids can cause "clinically important systemic adverse effects at licensed doses." 4 The United Kingdom datasheet for Beconase aqueous nasal spray (beclomethasone dipropionate) recognises the potential for children to develop growth retardation at licensed doses and the need to refer patients to paediatric specialists while they are being prescribed intranasal corticosteroids (Allen and Hanburys, Sept 1998).I question the omission of such key data from Weiner et al's systematic review; it may well tip the risk:benefit ratio away from the use of intranasal corticosteroids in children and, hence, affect the validity of the review's conclusions.